Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology
•A new diagnostic tool to distinguish vaccinated from infected immune response for HAV.•Clinical validation of HAV multiplex serology.•High sensitivity, specificity and accuracy to measure HAV infection and vaccination.•Using Luminex® technology to facilitate sero-epidemiological studies. Worldwide...
Gespeichert in:
| Veröffentlicht in: | Vaccine Jg. 35; H. 43; S. 5883 - 5889 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier Ltd
13.10.2017
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 0264-410X, 1873-2518, 1873-2518 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | •A new diagnostic tool to distinguish vaccinated from infected immune response for HAV.•Clinical validation of HAV multiplex serology.•High sensitivity, specificity and accuracy to measure HAV infection and vaccination.•Using Luminex® technology to facilitate sero-epidemiological studies.
Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.
HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.
HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.
HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. |
|---|---|
| AbstractList | •A new diagnostic tool to distinguish vaccinated from infected immune response for HAV.•Clinical validation of HAV multiplex serology.•High sensitivity, specificity and accuracy to measure HAV infection and vaccination.•Using Luminex® technology to facilitate sero-epidemiological studies.
Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.
HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.
HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.
HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.BACKGROUNDWorldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.METHODSHAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.RESULTSHAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns.CONCLUSIONHAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. BackgroundWorldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.MethodsHAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards.ResultsHAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy.ConclusionHAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals. HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards. HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy. HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. |
| Author | Sievers, Claudia Filomena, Angela Bohm, Katrin Krause, Gérard Schneiderhan-Marra, Nicole |
| Author_xml | – sequence: 1 givenname: Katrin surname: Bohm fullname: Bohm, Katrin organization: Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany – sequence: 2 givenname: Angela surname: Filomena fullname: Filomena, Angela organization: NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany – sequence: 3 givenname: Nicole surname: Schneiderhan-Marra fullname: Schneiderhan-Marra, Nicole organization: NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany – sequence: 4 givenname: Gérard surname: Krause fullname: Krause, Gérard organization: Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany – sequence: 5 givenname: Claudia surname: Sievers fullname: Sievers, Claudia email: sievec03@gmail.com organization: Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28919226$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkdGKEzEUhgdZcburj6AEvPFmapKZpBNEpCzqCgve6OJdyGTO1NNNk5rMFPsCPrcZ273pTYUD4ZDv_09y_qviwgcPRfGS0TmjTL5dz3fGWvQw55Qt5rTJpZ4UM9YsqpIL1lwUM8plXdaM_rgsrlJaU0pFxdSz4pI3iinO5az4c28cdmbA4Enoye3ynrQYNiY-QCR8SfoQSYd9DxH8gMblxqx8SAPaif8J26wdMJElQd-DHaAjxnfk8Dgzteg73GE3GpfImNCvyGZ0A24d_CYJYnBhtX9ePO3zPbw4ntfF908fv93clndfP3-5Wd6VVvDFUMpGtKruemtoy1sley57qYB3CyOYqhlXkrYVpaZhrWW1FVK0WcBMA61hvK2uizcH320Mv0ZIg95gsuCc8RDGpHnekWSC1_IsmudRpkSlVEZfn6DrMEafPzJRFW1EIybq1ZEa2w10ehsx73mvH8PIwLsDYGNIKUKvLQ7_ohmiQacZ1VP0eq2P0espek2bXJO9OFE_Djin-3DQQd77DiHqZBG8hQ5jzlN3Ac86vD9xsA49WuMeYP8f-r8G_-DL |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2018_05_015 crossref_primary_10_1128_JCM_01029_19 crossref_primary_10_1038_s41598_018_34927_1 crossref_primary_10_1002_rmv_2566 crossref_primary_10_1038_s41572_023_00461_2 crossref_primary_10_1016_j_bmcl_2019_04_043 crossref_primary_10_1016_j_jhep_2017_08_034 crossref_primary_10_1038_s41598_023_36739_4 crossref_primary_10_3390_pathogens11091059 |
| Cites_doi | 10.1007/s00103-014-2050-0 10.1038/317145a0 10.1002/jmv.21434 10.1016/S0022-1759(01)00376-3 10.1373/clinchem.2005.052381 10.1128/CMR.19.1.63-79.2006 10.1016/S0264-410X(00)00560-0 10.1016/j.hepres.2005.01.014 10.1097/INF.0000000000000042 10.1016/j.jpba.2008.09.020 10.1007/978-3-642-01080-4 10.1111/j.1523-5378.2009.00723.x 10.1002/jmv.1890400115 10.1093/infdis/jiw411 10.1001/jama.1994.03510410040030 10.1016/j.micinf.2004.03.001 10.1016/j.vaccine.2005.09.057 10.1128/JVI.66.4.2208-2216.1992 10.1016/j.biologicals.2015.07.004 10.1136/mp.55.4.214 10.1038/nature13806 10.3201/eid1704.101169 10.1097/INF.0b013e31806215c8 10.1097/INF.0b013e318190655c 10.2807/1560-7917.ES2014.19.50.20992 10.1099/0022-1317-73-6-1365 10.1111/j.1365-2893.2008.01029.x 10.1074/jbc.274.8.4527 10.1016/j.vaccine.2015.09.020 10.1038/nsb0395-224 10.1056/NEJM199208133270702 10.1086/514079 |
| ContentType | Journal Article |
| Copyright | 2017 The Authors Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Oct 13, 2017 |
| Copyright_xml | – notice: 2017 The Authors – notice: Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Oct 13, 2017 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2017.08.089 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic AGRICOLA Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 1873-2518 |
| EndPage | 5889 |
| ExternalDocumentID | 28919226 10_1016_j_vaccine_2017_08_089 S0264410X17311891 |
| Genre | Journal Article |
| GeographicLocations | Greece Argentina |
| GeographicLocations_xml | – name: Argentina – name: Greece |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADSLC AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGWPP AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- ~HD 3V. 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AESVU AFCTW AFKWA AJBFU AJOXV AMFUW LCYCR QYZTP RIG .GJ 29Q 9DU AAQXK AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFFHD AFJKZ AGHFR AGQPQ AHHHB AIGII ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- SAE SEW SIN SVS WUQ XPP ZGI ZXP ALIPV CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 7S9 L.6 |
| ID | FETCH-LOGICAL-c527t-685b94dfca0b2b96f26f69e2d7a519412960b300a81bc14c565bb941a8eba12b3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000413057700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Mon Sep 29 06:34:06 EDT 2025 Sat Sep 27 23:23:14 EDT 2025 Sat Nov 29 14:28:48 EST 2025 Thu Apr 03 07:01:15 EDT 2025 Sat Nov 29 02:25:45 EST 2025 Tue Nov 18 21:33:01 EST 2025 Fri Feb 23 02:21:15 EST 2024 Tue Oct 14 19:30:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 43 |
| Keywords | Vaccinology Serology Immunology Luminex assay Hepatitis A Virus |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c527t-685b94dfca0b2b96f26f69e2d7a519412960b300a81bc14c565bb941a8eba12b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.vaccine.2017.08.089 |
| PMID | 28919226 |
| PQID | 1943085859 |
| PQPubID | 105530 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2000615246 proquest_miscellaneous_1940195399 proquest_journals_1943085859 pubmed_primary_28919226 crossref_citationtrail_10_1016_j_vaccine_2017_08_089 crossref_primary_10_1016_j_vaccine_2017_08_089 elsevier_sciencedirect_doi_10_1016_j_vaccine_2017_08_089 elsevier_clinicalkey_doi_10_1016_j_vaccine_2017_08_089 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-13 |
| PublicationDateYYYYMMDD | 2017-10-13 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Michel, Waterboer, Kist, Pawlita (b0120) 2009; 14 Stewart, Morris, Purcell, Emerson (b0090) 1997; 176 Kyrka, Tragiannidis, Cassimos, Pantelaki, Tzoufi, Mavrokosta (b0170) 2009; 81 Bedard, Semler (b0010) 2004; 6 Shankar, Devanarayan, Amaravadi, Barrett, Bowsher, Finco-Kent (b0130) 2008; 48 Werzberger, Mensch, Kuter, Brown, Lewis, Sitrin (b0055) 1992; 327 WHO vaccine-preventable diseases: monitoring system. 2016 global summary; 2016. Paul-Ehrlich-Institut (Germany) – Hepatitis A vaccines n.d. Clavijo, Hole, Li, Collignon (b0140) 2006; 24 Smyth, Tate, Hoey, Lyons, Martin, Stuart (b0025) 1995; 2 Standing Committee on Immunization STIKO, Germany n.d. Wang, Ren, Gao, Hu, Sun, Li (b0160) 2015; 517 Kabrane-Lazizi, Emerson, Herzog, Purcell (b0095) 2001; 19 Hussain, Das, Husain, Asim, Chattopadhyay, Malik (b0040) 2005; 32 Rossmann, Arnold, Erickson, Frankenberger, Griffith, Hecht (b0020) 1985; 317 Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, et al. Single dose hepatitis A immunisation: 7·5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response. J Infect Dis 2016:jiw411. 10.1093/INFDIS/JIW411. Vacchino (b0180) 2008; 15 Centers for Disease C, Prevention. Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep 1998;46:ii–vii, 3–87. World Health Organization (b0005) 2000; 75 Nainan, Xia, Vaughan, Margolis (b0015) 2006; 19 Innis, Snitbhan, Kunasol, Laorakpongse, Poopatanakool, Kozik (b0060) 1994; 271 Barkai, Belmaker, Givon-Lavi, Dagan (b0105) 2009; 28 Robertson, Jia, Tian, Margolis, Summers, Ehrenfeld (b0135) 1993; 40 Ping, Lemon (b0165) 1992; 66 Probst, Jecht, Gauss-Muller (b0155) 1999; 274 Smyth, Martin (b0030) 2002; 55 Pérez-Sautu, Costafreda, Caylà, Tortajada, Lite, Bosch (b0035) 2011; 17 Harries, Monazahian, Wenzel, Jilg, Weber, Ehlers (b0185) 2014; 19 Schwabe U, Paffrath D. Arzneiverordnungsreport; 2009. Biswal, Subramaniam, Ranjan, Sharma, Misri, Pattnaik (b0145) 2015; 43 Tacken, Daus, Feenstra, van Gennip, van Rijn (b0150) 2015; 33 Vizzotti, Gonzalez, Gentile, Rearte, Ramonet, Canero-Velasco (b0110) 2014; 33 Montano-Remacha, Ricotta, Alfonsi, Bella, Tosti, Ciccaglione (b0190) 2014 Van Der Wielen, Vertruyen, Froesner, Ibanez, Hunt, Herzog (b0065) 2007; 26 Sehr, Zumbach, Pawlita (b0115) 2001; 253 Schultze, Akmatov, Castell, Karch, Ahrens, Gunther (b0100) 2014; 57 Waterboer, Sehr, Michael, Franceschi, Nieland, Joos (b0125) 2005; 51 Robertson, Jansen, Khanna, Totsuka, Nainan, Siegl (b0045) 1992; 73 Werzberger (10.1016/j.vaccine.2017.08.089_b0055) 1992; 327 Kyrka (10.1016/j.vaccine.2017.08.089_b0170) 2009; 81 World Health Organization (10.1016/j.vaccine.2017.08.089_b0005) 2000; 75 Robertson (10.1016/j.vaccine.2017.08.089_b0045) 1992; 73 Pérez-Sautu (10.1016/j.vaccine.2017.08.089_b0035) 2011; 17 Ping (10.1016/j.vaccine.2017.08.089_b0165) 1992; 66 Hussain (10.1016/j.vaccine.2017.08.089_b0040) 2005; 32 Innis (10.1016/j.vaccine.2017.08.089_b0060) 1994; 271 Clavijo (10.1016/j.vaccine.2017.08.089_b0140) 2006; 24 Waterboer (10.1016/j.vaccine.2017.08.089_b0125) 2005; 51 10.1016/j.vaccine.2017.08.089_b0075 Van Der Wielen (10.1016/j.vaccine.2017.08.089_b0065) 2007; 26 10.1016/j.vaccine.2017.08.089_b0175 10.1016/j.vaccine.2017.08.089_b0070 Michel (10.1016/j.vaccine.2017.08.089_b0120) 2009; 14 10.1016/j.vaccine.2017.08.089_b0050 Probst (10.1016/j.vaccine.2017.08.089_b0155) 1999; 274 Montano-Remacha (10.1016/j.vaccine.2017.08.089_b0190) 2014 Robertson (10.1016/j.vaccine.2017.08.089_b0135) 1993; 40 Bedard (10.1016/j.vaccine.2017.08.089_b0010) 2004; 6 Barkai (10.1016/j.vaccine.2017.08.089_b0105) 2009; 28 Sehr (10.1016/j.vaccine.2017.08.089_b0115) 2001; 253 Tacken (10.1016/j.vaccine.2017.08.089_b0150) 2015; 33 10.1016/j.vaccine.2017.08.089_b0080 Shankar (10.1016/j.vaccine.2017.08.089_b0130) 2008; 48 Smyth (10.1016/j.vaccine.2017.08.089_b0030) 2002; 55 Biswal (10.1016/j.vaccine.2017.08.089_b0145) 2015; 43 Rossmann (10.1016/j.vaccine.2017.08.089_b0020) 1985; 317 Smyth (10.1016/j.vaccine.2017.08.089_b0025) 1995; 2 10.1016/j.vaccine.2017.08.089_b0085 Vizzotti (10.1016/j.vaccine.2017.08.089_b0110) 2014; 33 Wang (10.1016/j.vaccine.2017.08.089_b0160) 2015; 517 Vacchino (10.1016/j.vaccine.2017.08.089_b0180) 2008; 15 Schultze (10.1016/j.vaccine.2017.08.089_b0100) 2014; 57 Stewart (10.1016/j.vaccine.2017.08.089_b0090) 1997; 176 Harries (10.1016/j.vaccine.2017.08.089_b0185) 2014; 19 Nainan (10.1016/j.vaccine.2017.08.089_b0015) 2006; 19 Kabrane-Lazizi (10.1016/j.vaccine.2017.08.089_b0095) 2001; 19 29907320 - Vaccine. 2018 Jun 22;36(27):3883-3884 |
| References_xml | – volume: 33 start-page: 84 year: 2014 end-page: 88 ident: b0110 article-title: Impact of the single-dose immunization strategy against hepatitis A in Argentina publication-title: Pediatr Infect Dis J – volume: 17 start-page: 734 year: 2011 end-page: 737 ident: b0035 article-title: Hepatitis A virus vaccine escape variants and potential new serotype emergence publication-title: Emerg Infect Dis – volume: 81 start-page: 582 year: 2009 end-page: 587 ident: b0170 article-title: Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination publication-title: J Med Virol – volume: 48 start-page: 1267 year: 2008 end-page: 1281 ident: b0130 article-title: Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products publication-title: J Pharm Biomed Anal – volume: 327 start-page: 453 year: 1992 end-page: 457 ident: b0055 article-title: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children publication-title: N Engl J Med – volume: 43 start-page: 504 year: 2015 end-page: 511 ident: b0145 article-title: Marker vaccine potential of foot-and-mouth disease virus with large deletion in the non-structural proteins 3A and 3B publication-title: Biologicals – volume: 19 start-page: 63 year: 2006 end-page: 79 ident: b0015 article-title: Diagnosis of hepatitis a virus infection: a molecular approach publication-title: Clin Microbiol Rev – volume: 271 start-page: 1328 year: 1994 end-page: 1334 ident: b0060 article-title: Protection against hepatitis A by an inactivated vaccine publication-title: JAMA – volume: 517 start-page: 85 year: 2015 end-page: 88 ident: b0160 article-title: Hepatitis A virus and the origins of picornaviruses publication-title: Nature – volume: 73 start-page: 1365 year: 1992 end-page: 1377 ident: b0045 article-title: Genetic relatedness of hepatitis A virus strains recovered from different geographical regions publication-title: J Gen Virol – volume: 14 start-page: 525 year: 2009 end-page: 535 ident: b0120 article-title: Helicobacter pylori multiplex serology publication-title: Helicobacter – reference: WHO vaccine-preventable diseases: monitoring system. 2016 global summary; 2016. – volume: 40 start-page: 76 year: 1993 end-page: 82 ident: b0135 article-title: Antibody response to nonstructural proteins of hepatitis A virus following infection publication-title: J Med Virol – volume: 66 start-page: 2208 year: 1992 end-page: 2216 ident: b0165 article-title: Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies publication-title: J Virol – volume: 75 start-page: 38 year: 2000 end-page: 44 ident: b0005 article-title: Hepatitis A vaccines publication-title: Wkly Epidemiol Rec – volume: 2 start-page: 224 year: 1995 end-page: 231 ident: b0025 article-title: Implications for viral uncoating from the structure of bovine enterovirus publication-title: Nat Struct Biol – volume: 26 start-page: 705 year: 2007 end-page: 710 ident: b0065 article-title: Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years publication-title: Pediatr Infect Dis J – volume: 176 start-page: 593 year: 1997 end-page: 601 ident: b0090 article-title: Detection of antibodies to the nonstructural 3C proteinase of hepatitis A virus publication-title: J Infect Dis – volume: 19 start-page: 2878 year: 2001 end-page: 2883 ident: b0095 article-title: Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children publication-title: Vaccine – volume: 57 start-page: 1292 year: 2014 end-page: 1299 ident: b0100 article-title: Collection of vaccination data in the German National Cohort: findings of a feasibility study in three study centers publication-title: Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz – reference: Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, et al. Single dose hepatitis A immunisation: 7·5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response. J Infect Dis 2016:jiw411. 10.1093/INFDIS/JIW411. – volume: 6 start-page: 702 year: 2004 end-page: 713 ident: b0010 article-title: Regulation of picornavirus gene expression publication-title: Microbes Infect – reference: Schwabe U, Paffrath D. Arzneiverordnungsreport; 2009. – reference: Centers for Disease C, Prevention. Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep 1998;46:ii–vii, 3–87. – volume: 28 start-page: 391 year: 2009 end-page: 393 ident: b0105 article-title: The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community publication-title: Pediatr Infect Dis J – volume: 24 start-page: 1693 year: 2006 end-page: 1704 ident: b0140 article-title: Simultaneous detection of antibodies to foot-and-mouth disease non-structural proteins 3ABC, 3D, 3A and 3B by a multiplexed Luminex assay to differentiate infected from vaccinated cattle publication-title: Vaccine – volume: 274 start-page: 4527 year: 1999 end-page: 4531 ident: b0155 article-title: Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A publication-title: J Biol Chem – volume: 32 start-page: 16 year: 2005 end-page: 24 ident: b0040 article-title: Hepatitis A viral genotypes and clinical relevance: clinical and molecular characterization of hepatitis A virus isolates from northern India publication-title: Hepatol Res – volume: 317 start-page: 145 year: 1985 end-page: 153 ident: b0020 article-title: Structure of a human common cold virus and functional relationship to other picornaviruses publication-title: Nature – volume: 19 start-page: 20992 year: 2014 ident: b0185 article-title: Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012 publication-title: Euro Surveill – volume: 55 start-page: 214 year: 2002 end-page: 219 ident: b0030 article-title: Picornavirus uncoating publication-title: Mol Pathol – reference: Paul-Ehrlich-Institut (Germany) – Hepatitis A vaccines n.d. – volume: 51 start-page: 1845 year: 2005 end-page: 1853 ident: b0125 article-title: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins publication-title: Clin Chem – start-page: 19 year: 2014 ident: b0190 article-title: Hepatitis A outbreak in Italy, 2013: a matched case-control study publication-title: Euro Surveill – reference: Standing Committee on Immunization STIKO, Germany n.d. – volume: 253 start-page: 153 year: 2001 end-page: 162 ident: b0115 article-title: A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology publication-title: J Immunol Methods – volume: 15 start-page: 47 year: 2008 end-page: 50 ident: b0180 article-title: Incidence of Hepatitis A in Argentina after vaccination publication-title: J Viral Hepat – volume: 33 start-page: 5539 year: 2015 end-page: 5545 ident: b0150 article-title: Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue publication-title: Vaccine – volume: 75 start-page: 38 year: 2000 ident: 10.1016/j.vaccine.2017.08.089_b0005 article-title: Hepatitis A vaccines publication-title: Wkly Epidemiol Rec – volume: 57 start-page: 1292 year: 2014 ident: 10.1016/j.vaccine.2017.08.089_b0100 article-title: Collection of vaccination data in the German National Cohort: findings of a feasibility study in three study centers publication-title: Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz doi: 10.1007/s00103-014-2050-0 – volume: 317 start-page: 145 year: 1985 ident: 10.1016/j.vaccine.2017.08.089_b0020 article-title: Structure of a human common cold virus and functional relationship to other picornaviruses publication-title: Nature doi: 10.1038/317145a0 – volume: 81 start-page: 582 year: 2009 ident: 10.1016/j.vaccine.2017.08.089_b0170 article-title: Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination publication-title: J Med Virol doi: 10.1002/jmv.21434 – volume: 253 start-page: 153 year: 2001 ident: 10.1016/j.vaccine.2017.08.089_b0115 article-title: A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology publication-title: J Immunol Methods doi: 10.1016/S0022-1759(01)00376-3 – ident: 10.1016/j.vaccine.2017.08.089_b0080 – volume: 51 start-page: 1845 year: 2005 ident: 10.1016/j.vaccine.2017.08.089_b0125 article-title: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins publication-title: Clin Chem doi: 10.1373/clinchem.2005.052381 – volume: 19 start-page: 63 year: 2006 ident: 10.1016/j.vaccine.2017.08.089_b0015 article-title: Diagnosis of hepatitis a virus infection: a molecular approach publication-title: Clin Microbiol Rev doi: 10.1128/CMR.19.1.63-79.2006 – volume: 19 start-page: 2878 year: 2001 ident: 10.1016/j.vaccine.2017.08.089_b0095 article-title: Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children publication-title: Vaccine doi: 10.1016/S0264-410X(00)00560-0 – volume: 32 start-page: 16 year: 2005 ident: 10.1016/j.vaccine.2017.08.089_b0040 article-title: Hepatitis A viral genotypes and clinical relevance: clinical and molecular characterization of hepatitis A virus isolates from northern India publication-title: Hepatol Res doi: 10.1016/j.hepres.2005.01.014 – volume: 33 start-page: 84 year: 2014 ident: 10.1016/j.vaccine.2017.08.089_b0110 article-title: Impact of the single-dose immunization strategy against hepatitis A in Argentina publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000000042 – volume: 48 start-page: 1267 year: 2008 ident: 10.1016/j.vaccine.2017.08.089_b0130 article-title: Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2008.09.020 – ident: 10.1016/j.vaccine.2017.08.089_b0070 – ident: 10.1016/j.vaccine.2017.08.089_b0075 doi: 10.1007/978-3-642-01080-4 – volume: 14 start-page: 525 year: 2009 ident: 10.1016/j.vaccine.2017.08.089_b0120 article-title: Helicobacter pylori multiplex serology publication-title: Helicobacter doi: 10.1111/j.1523-5378.2009.00723.x – volume: 40 start-page: 76 year: 1993 ident: 10.1016/j.vaccine.2017.08.089_b0135 article-title: Antibody response to nonstructural proteins of hepatitis A virus following infection publication-title: J Med Virol doi: 10.1002/jmv.1890400115 – ident: 10.1016/j.vaccine.2017.08.089_b0175 doi: 10.1093/infdis/jiw411 – volume: 271 start-page: 1328 year: 1994 ident: 10.1016/j.vaccine.2017.08.089_b0060 article-title: Protection against hepatitis A by an inactivated vaccine publication-title: JAMA doi: 10.1001/jama.1994.03510410040030 – volume: 6 start-page: 702 year: 2004 ident: 10.1016/j.vaccine.2017.08.089_b0010 article-title: Regulation of picornavirus gene expression publication-title: Microbes Infect doi: 10.1016/j.micinf.2004.03.001 – volume: 24 start-page: 1693 year: 2006 ident: 10.1016/j.vaccine.2017.08.089_b0140 article-title: Simultaneous detection of antibodies to foot-and-mouth disease non-structural proteins 3ABC, 3D, 3A and 3B by a multiplexed Luminex assay to differentiate infected from vaccinated cattle publication-title: Vaccine doi: 10.1016/j.vaccine.2005.09.057 – volume: 66 start-page: 2208 year: 1992 ident: 10.1016/j.vaccine.2017.08.089_b0165 article-title: Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies publication-title: J Virol doi: 10.1128/JVI.66.4.2208-2216.1992 – ident: 10.1016/j.vaccine.2017.08.089_b0085 – volume: 43 start-page: 504 year: 2015 ident: 10.1016/j.vaccine.2017.08.089_b0145 article-title: Marker vaccine potential of foot-and-mouth disease virus with large deletion in the non-structural proteins 3A and 3B publication-title: Biologicals doi: 10.1016/j.biologicals.2015.07.004 – start-page: 19 year: 2014 ident: 10.1016/j.vaccine.2017.08.089_b0190 article-title: Hepatitis A outbreak in Italy, 2013: a matched case-control study publication-title: Euro Surveill – volume: 55 start-page: 214 year: 2002 ident: 10.1016/j.vaccine.2017.08.089_b0030 article-title: Picornavirus uncoating publication-title: Mol Pathol doi: 10.1136/mp.55.4.214 – ident: 10.1016/j.vaccine.2017.08.089_b0050 – volume: 517 start-page: 85 year: 2015 ident: 10.1016/j.vaccine.2017.08.089_b0160 article-title: Hepatitis A virus and the origins of picornaviruses publication-title: Nature doi: 10.1038/nature13806 – volume: 17 start-page: 734 year: 2011 ident: 10.1016/j.vaccine.2017.08.089_b0035 article-title: Hepatitis A virus vaccine escape variants and potential new serotype emergence publication-title: Emerg Infect Dis doi: 10.3201/eid1704.101169 – volume: 26 start-page: 705 year: 2007 ident: 10.1016/j.vaccine.2017.08.089_b0065 article-title: Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31806215c8 – volume: 28 start-page: 391 year: 2009 ident: 10.1016/j.vaccine.2017.08.089_b0105 article-title: The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e318190655c – volume: 19 start-page: 20992 year: 2014 ident: 10.1016/j.vaccine.2017.08.089_b0185 article-title: Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES2014.19.50.20992 – volume: 73 start-page: 1365 issue: Pt 6 year: 1992 ident: 10.1016/j.vaccine.2017.08.089_b0045 article-title: Genetic relatedness of hepatitis A virus strains recovered from different geographical regions publication-title: J Gen Virol doi: 10.1099/0022-1317-73-6-1365 – volume: 15 start-page: 47 issue: Suppl 2 year: 2008 ident: 10.1016/j.vaccine.2017.08.089_b0180 article-title: Incidence of Hepatitis A in Argentina after vaccination publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2008.01029.x – volume: 274 start-page: 4527 year: 1999 ident: 10.1016/j.vaccine.2017.08.089_b0155 article-title: Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A publication-title: J Biol Chem doi: 10.1074/jbc.274.8.4527 – volume: 33 start-page: 5539 year: 2015 ident: 10.1016/j.vaccine.2017.08.089_b0150 article-title: Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue publication-title: Vaccine doi: 10.1016/j.vaccine.2015.09.020 – volume: 2 start-page: 224 year: 1995 ident: 10.1016/j.vaccine.2017.08.089_b0025 article-title: Implications for viral uncoating from the structure of bovine enterovirus publication-title: Nat Struct Biol doi: 10.1038/nsb0395-224 – volume: 327 start-page: 453 year: 1992 ident: 10.1016/j.vaccine.2017.08.089_b0055 article-title: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children publication-title: N Engl J Med doi: 10.1056/NEJM199208133270702 – volume: 176 start-page: 593 year: 1997 ident: 10.1016/j.vaccine.2017.08.089_b0090 article-title: Detection of antibodies to the nonstructural 3C proteinase of hepatitis A virus publication-title: J Infect Dis doi: 10.1086/514079 – reference: 29907320 - Vaccine. 2018 Jun 22;36(27):3883-3884 |
| SSID | ssj0005319 |
| Score | 2.297033 |
| Snippet | •A new diagnostic tool to distinguish vaccinated from infected immune response for HAV.•Clinical validation of HAV multiplex serology.•High sensitivity,... Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination... BackgroundWorldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5883 |
| SubjectTerms | Adolescent Adult Antigens Assaying Beads Biomarkers Biomarkers - blood capsid Capsid Proteins - blood Capsid Proteins - immunology Child Child, Preschool childhood Children Cysteine Endopeptidases - blood Cysteine Endopeptidases - immunology Diagnostic systems Differentiation E coli Enzyme-linked immunosorbent assay Fluorescence Foot & mouth disease Genomes Glutathione Glutathione transferase Hepatitis Hepatitis A Hepatitis A - blood Hepatitis A - diagnosis Hepatitis A - immunology Hepatitis A - virology Hepatitis A Antibodies - blood Hepatitis A Antibodies - immunology Hepatitis A Virus Hepatitis A virus - immunology Hepatovirus A Humans Immune status Immunization Immunoglobulin G Immunoglobulin G - blood Immunoglobulin G - immunology Immunoglobulin M Immunoglobulin M - blood Immunoglobulin M - immunology Immunoglobulins Immunology Infant Infant, Newborn Infections Luminex assay magnetism Medical diagnosis Multiplexing outbreak investigation Outbreaks Population studies Proteins Public health Risk assessment Serology Vaccination Vaccination - methods Vaccines Vaccinology viral nonstructural proteins Viral Proteins - blood Viral Proteins - immunology Viruses |
| Title | Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X17311891 https://dx.doi.org/10.1016/j.vaccine.2017.08.089 https://www.ncbi.nlm.nih.gov/pubmed/28919226 https://www.proquest.com/docview/1943085859 https://www.proquest.com/docview/1940195399 https://www.proquest.com/docview/2000615246 |
| Volume | 35 |
| WOSCitedRecordID | wos000413057700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M7P dateStart: 20020101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0R dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Healthcare Administration Database customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1873-2518 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6xDSYkxI9uQGFURkJ7WrbESW3nCZVp0x5YiaZS9S1yHAc2Te1ou4n9A_zd3NlJ-sIYEi8nWfW1Vno5f_Z9dwfwwfaTshBWBZUIJR5Qqn6gS10FMrayFFoL44skfZbDoZpM0qy-cFvUtMrGJzpHXc4M3ZEfRFQnnIJY6cerHwF1jaLoat1CYw02qEpC7Kh72YriEbvGHnjMSIIkCierDJ6Di_0bbSh0Tewu6ap4Uqf3P-9Nd2FPtwcdP_vf1T-HpzX6ZANvLi_ggZ124JHvR3nbgc3TOtLegd3M17S-3WOjVYrWYo_tsmxV7Rp1nviLP-bzmTrQGRPBxmX5subrtuDXGPG-b9_EZhU7GYwZJf4TN2jO-IAhdGZNrxb0OZc4cBRA_E2a_90S8Xt5vmAD5uljtmR6WjL_eDUNz9vUsgUjNv831pAlfzJ8z9xyt-Hr8dHo8CSoW0AEps_lMhCqX6RJWRkdFrxIRcVFJVLLS6kReiYIVkRYxGGoEX2bKDEITwtUiLSyhY54Eb-E9elsal8Ds7GxFZWvkzpNEpPqkJeFVCotRV8XlepC0vz5uanro1Objsu8IcJd5LXN5GQzObXvVGkX9lu1K18g5D4F0VhW3mS_or_OcQu7T1G1ijU88rDnX1R3GrPMax-1yFc22YX37cfoXShkpKd2du3mUEYpoti753CPi3kiuvDKvx7tk8DjPB4huHjz9wW8hce0WsIEUbwD68v5tX0HD80NGta8B2vybExyIp1UKNVh1IONT0fD7AxHp6GXI5L8S8-5gd_AV1-A |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6V8pQQj_AKFBgk6Klu7bWztg8IRUCVqknUQ4hyM-v1GlpVSUnSQv4AP4ffyIzXm1wo5dIDR8s79mo9Mzvj_WY-gNemFRW5NIlXSj-mBKVseapQpReHJi6kUlLbJknduN9PRqP0YA1-uVoYhlU6n1g56mKi-R_5TsB9wvkQK3138s1j1ig-XXUUGlYt9s3iO6Vss7d7H-j7vhFi9-PgfcerWQU83RLx3JNJK0-jotTKz0WeylLIUqZGFLGiaCai_U_6eej7igI6HUSaIp6cBAKVmFwFIg_puVfgKvfVYwhhzx-sICVhRSRCaU3kRYE_WlUM7RxtnynNR-WMJourrqHMLP_nvfC8WLfa83bv_m-rdQ_u1NE1tq053Ic1M27Adcu3uWjAjV6NJGjA5oHt2b3YwsGqBG22hZt4sOrmTTK37Y9NtPVaDWgMGUBUVTGje9wD-DmkfMbSU-GkxE57iNzYgLFPUxRtpNQAHRcN-dRjuqggjvROHv_VMLB9fjjDNlp4nClQjQu0n1Px5eGydG6GXK3wBR0Y9AeSH6mm-xA-XcryPoL18WRsngCaUJuS2_PFKo0inSpfFHmcJGkhWyovkyZETtkyXfd_ZxqS48wB_Y6yWkcz1tGM6UmTtAnbS7ET2wDlIgHpNDlz1b20H2W0RV8kmCwF6_DPhnX_IrrhzCCrffAsW9lAE14tb5P35CMxNTaT02oMV8xSlH7-GGHjfhHJJjy25rhcCZGklCIJ-fTvE3gJNzuDXjfr7vX3n8EtnjnHP0G4Aevz6al5Dtf0GSnZ9EXlUBA-X7ZN_gZPL7Pk |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEB6VAhUS4if8BQoMEvRUN_baWdsHhKKWqFVLlEOJcjPr9RpaVUlJ0kJegIfi6ZjxehMOlHLpgaPlHXu1npmd8X4zH8Br046KXJrEK6UfU4JStj1VqNKLQxMXUimpbZOkg7jXS4bDtL8CP10tDMMqnU-sHHUx1vyPvBVwn3A-xEpbZQ2L6O90351-9ZhBik9aHZ2GVZF9M_9G6dv07d4Ofes3QnTfH27vejXDgKfbIp55MmnnaVSUWvm5yFNZClnK1IgiVhTZRLQXSj8PfV9RcKeDSFP0k5NAoBKTq0DkIT33GlyPQ9JirlLf_g1eElakIpTiRF4U-MNl9VDreOtcaT42Z2RZXHUQZZb5P--LF8W91f7Xvfs_r9w9uFNH3dixZnIfVsyoATctD-e8AWsfaoRBAzb6tpf3fBMPl6Vp003cwP6yyzfJ3LY_PNHWcTWgMWBgUVXdjO5xD-DHgPIcS1uF4xJ3OwPkhgeMiZqg6CClDOg4asjXntBFBX2kd_L4L4YB77OjKXbQwuZMgWpUoP20ii-PFiV1U-Qqhs_oQKLfkfxLNd2H8PFKlvcRrI7GI_ME0ITalNy2L1ZpFOlU-aLI4yRJC9lWeZk0IXKKl-m6LzzTk5xkDgB4nNX6mrG-ZkxbmqRN2FqIndrGKJcJSKfVmav6pX0qo637MsFkIViHhTbc-xfRdWcSWe2bp9nSHprwanGbvCoflamRGZ9VY7iSlqL3i8cImw-ISDbhsTXNxUqIJKXUScinf5_AS1gjU8wO9nr7z-AWT5zDoiBch9XZ5Mw8hxv6nHRs8qLyLQifrtokfwGP07xi |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+HAV+biomarker+2A+for+differential+diagnostic+of+hepatitis+A+infected+and+vaccinated+individuals+using+multiplex+serology&rft.jtitle=Vaccine&rft.au=Bohm%2C+Katrin&rft.au=Filomena%2C+Angela&rft.au=Schneiderhan-Marra%2C+Nicole&rft.au=Krause%2C+G%C3%A9rard&rft.date=2017-10-13&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=35&rft.issue=43&rft.spage=5883&rft.epage=5889&rft_id=info:doi/10.1016%2Fj.vaccine.2017.08.089&rft.externalDocID=S0264410X17311891 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |